uniQure N.V. 8-K

What Happened

• On June 17, 2026, uniQure N.V. (QURE) announced via 8-K and press release that it plans to submit a Biologics License Application (BLA) for AMT-130 in Huntington’s disease during the third quarter of 2026.
• This follows a Type B meeting with the U.S. Food and Drug Administration (FDA), in which the FDA communicated that the 3-year analysis from uniQure’s Phase I/II study would be acceptable as the primary basis for a BLA seeking accelerated approval. The company expects to receive the final meeting minutes within 30 days.

Key Details

• Planned BLA submission timing: third quarter of 2026 (Q3 2026).
• FDA feedback: 3-year Phase I/II analysis acceptable as primary basis for accelerated approval.
• FDA request: alignment on the confirmatory study design prior to submission, including consideration of a concurrent control of standard of care that would not include a sham procedure.
• uniQure commitment: company says it will conduct the required confirmatory study without delay.
• Press release attached to the 8-K as Exhibit 99.1.

Why It Matters

• The FDA’s acceptance of the 3‑year Phase I/II analysis as an acceptable primary basis gives uniQure a clearer regulatory path and a near-term filing target (Q3 2026), which is a material development for the program’s timeline.
• The FDA’s requirement to align on a confirmatory trial design (including a non-sham concurrent control) identifies a key next step that will affect post-approval evidence generation and timing.
• For investors, this filing is a program-specific regulatory update — it does not include financial results — and it highlights both progress toward a potential accelerated approval and remaining regulatory requirements that could affect commercialization timing and risk.